BioSpace

argenx shares have fallen more than 13% after the surprise futility finding, which overshadowed a mid-stage celiac disease win for a separate asset acquired in the company’s $2.2 billion Forte Biosciences, Inc. buy. https://hubs.li/Q04zCTBh0

After one patient death prompted an FDA hold this spring, Newron Pharmaceuticals SpA has now shared that a total of four fatalities have been recorded among participants receiving its schizophrenia candidate. A fifth death was recorded among those taking the placebo. https://hubs.li/Q04zC5v50

For the second time in a week, Zealand Pharma’s weight loss pipeline has delivered mixed results, this time in a Phase 2 trial for the Roche-partnered asset petrelintide. https://hubs.li/Q04zBZLd0

Matchpoint Therapeutics’ lead asset is the oral T cell modulator MPT-062, which the biotech plans to advance into clinical development for autoimmune and inflammatory conditions next year. https://hubs.li/Q04zBB700

In today's episode of Denatured, you’ll hear from Jennifer McMahon, partner at Seroba and Joey Mason, venture partner at Claret Capital. We dig into how venture debt buys time when equity can’t and how Europe’s funding gaps, tranching habits and slower urgency shape who uses it well. Listen to the full episode here: https://hubs.li/Q04zCfsv0

Caribou Biosciences, co-founded by Nobel Prize-winning CRISPR pioneer Jennifer Doudna, is discontinuing its entire clinical-stage pipeline and executing “substantial” workforce cuts amid a financing freeze in the CAR T space. https://hubs.li/Q04zB49J0

Biotechs developing therapeutics to treat rare diseases include two that received FDA approvals this year for drugs to treat spinal muscular atrophy and Alexander disease. https://hubs.li/Q04zB3yy0

In this episode of Denatured, you’ll hear from Jennifer McMahon, partner at Seroba. and Joey Mason, venture partner at Claret Capital Partners. We dig into how venture debt buys time when equity can’t and how Europe’s funding gaps, tranching habits and slower urgency shape who uses it well. https://hubs.li/Q04zB3rP0

Big Pharma companies including Bristol Myers Squibb, Johnson & Johnson and Novartis are among those that made or planned layoffs in Q3. Those cuts could affect over 1,800 employees, with New Jersey the hardest-hit state. https://hubs.li/Q04zB2d70

The Takeda spinout showed that a high dose of solengepras can shorten the periods during which difficult Parkinson’s disease symptoms like involuntary movements and sleepiness. https://hubs.li/Q04zt9bZ0